Activity from announced rounds
RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.
Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.
Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
Develops oligonucleotide therapeutics targeting chronic hepatitis B
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops highly targeted, small molecule medicines for cancer and rare diseases
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
Develops medicines targeting historically undruggable protein targets in cancer